Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)
- Wednesday, December 18, 2019, 7:19
- Environment
- Add a comment
INDIANAPOLIS, Dec. 18, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm). The objective of the TRIUMPH study (Preventive Treatment of Migraine: Outcomes for Patients in…
About the Author
adminasapcorp has written 42197 stories on this site.